Maximizing Weight Loss on Ozempic: Strategies and Insights for Success

Last reviewed: July 7, 2026

Last updated: July 7, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Before you can maximize weight loss "on Ozempic," it is worth being precise about what Ozempic is. The Ozempic prescribing information indicates it as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, and to reduce cardiorenal risk in adults with type 2 diabetes and chronic kidney disease. It carries no weight-management indication. The semaglutide product the FDA approved for weight reduction is Wegovy, and nearly all of the published evidence on how to get more out of semaglutide for weight comes from that program. That evidence is unusually clear about what actually moves the number — and about what does not.

Start With the Right Evidence Base

The Ozempic trials were diabetes trials. Their primary endpoint was HbA1c reduction, and body weight appears in labeling as a secondary observation. In the monotherapy trial, mean body weight change from baseline to week 30 was −3.8 kg with 0.5 mg and −4.7 kg with 1 mg versus −1.2 kg with placebo. In the trial comparing 2 mg with 1 mg, week 40 changes were −6.4 kg and −5.6 kg, a difference the label reports as not statistically significant.

The weight program is a different set of studies with different designs, different durations, and different populations. If your question is how to maximize weight loss, that is the literature that answers it — and using it honestly means acknowledging it was generated with a higher-dose product approved for a different indication.

Every Protocol Paired the Medication With Something

Both indications are written as adjuncts, and the trials enforced that. In the pivotal 68-week weight trial reported in the New England Journal of Medicine, all 1,961 participants — semaglutide and placebo alike — received lifestyle intervention. Mean body weight change was −14.9 percent with semaglutide 2.4 mg versus −2.4 percent with placebo.

That placebo figure is the quiet lesson. Structured lifestyle intervention alone produced measurable change in a population that had presumably tried to lose weight before. The medication did not replace that scaffolding; it was layered on top of it, and every headline percentage you have seen includes it.

What Adding Intensive Behavioral Therapy Did

The most direct test of "maximizing" is STEP 3, a 68-week randomized trial at 41 US sites in 611 adults without diabetes. Everyone received intensive behavioral therapy — 30 counseling visits across the trial — plus a low-calorie diet for the first eight weeks. Participants were randomized to semaglutide 2.4 mg or placebo on top of that.

Estimated mean body weight change at week 68 was −16.0 percent with semaglutide versus −5.7 percent with placebo, a difference of −10.3 percentage points. At least 5 percent loss was achieved by 86.6 percent versus 47.6 percent; at least 10 percent by 75.3 percent versus 27.0 percent; at least 15 percent by 55.8 percent versus 13.2 percent.

Compare the placebo arms across trials: 5.7 percent with intensive behavioral therapy versus 2.4 percent with standard lifestyle intervention. The behavioral component is not filler. It carried more than twice the effect on its own.

Persistence Outperforms Intensity

The single most consequential variable in this literature is whether treatment continues. STEP 4 was built to isolate exactly that. After a 20-week run-in during which 902 participants escalated to semaglutide 2.4 mg and lost a mean 10.6 percent, 803 who reached the maintenance dose were randomized to continue semaglutide or switch to placebo for 48 more weeks, with lifestyle intervention in both arms.

From week 20 to week 68, mean body weight change was −7.9 percent with continued semaglutide versus +6.9 percent with the switch to placebo — a 14.8 percentage point gap. Waist circumference, systolic blood pressure, and physical functioning scores all favored continuation. Gastrointestinal events were reported in 49.1 percent of those who continued versus 26.1 percent on placebo, and discontinuation rates due to adverse events were similar between the groups.

What Happens After Treatment Ends

The STEP 1 trial extension followed 327 participants for a year after both study drug and lifestyle intervention were withdrawn at week 68. Semaglutide participants had lost a mean 17.3 percent during treatment. By week 120 they had regained 11.6 percentage points, ending at a net 5.6 percent reduction. Cardiometabolic improvements largely reverted toward baseline.

The authors' conclusion was that the findings confirm the chronicity of obesity and suggest ongoing treatment is required to maintain improvements in weight and health. That reframes "maximizing" from a sprint toward a peak number into a question about what is sustainable for years.

Dose Is a Clinical Decision, Not an Optimization Lever

It is tempting to treat dose as the throttle. The label does not describe it that way. Ozempic labeling instructs prescribers to follow a stepwise escalation specifically "to reduce the risk of gastrointestinal adverse reactions," with a maximum recommended dosage of 2 mg once weekly. The escalation exists to manage tolerability, and in the 2 mg versus 1 mg trial the additional weight change at the higher dose was not statistically significant.

Any change to a regimen — dose, timing, duration, or whether to continue at all — belongs to the clinician who wrote the prescription and to the pharmacy label that came with your medication. Those documents account for your other medications, your kidney and liver function, and your history in ways no general article can. That is not a hedge; it is where the decision legitimately sits.

What Compounded Semaglutide Does and Does Not Change

Compounded semaglutide is not an FDA-approved finished product, and the FDA does not review compounded preparations for safety, effectiveness, or quality before marketing. It is prepared by a licensed pharmacy pursuant to a prescription for an individual patient. Wegovy and Ozempic are the approved semaglutide brands; a compounded preparation is not a generic version of either, since neither has an approved generic equivalent.

What compounding does not change is the evidence. The behavioral scaffolding, the multi-month time horizon, and the continuation effect documented in the trials apply regardless of where a prescription is filled. PlexusDx works exclusively with licensed 503A compounding pharmacies and pairs every protocol with clinician oversight, because the oversight is the part the data says matters.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test ($298) to personalize your protocol from day one.

Frequently Asked Questions

Is Ozempic approved for weight loss?

No. Ozempic labeling lists three indications, all in adults with type 2 diabetes: improving glycemic control as an adjunct to diet and exercise, reducing the risk of major adverse cardiovascular events in those with established cardiovascular disease, and reducing the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in those with chronic kidney disease. Wegovy is the semaglutide product FDA-approved for weight reduction.

Does adding behavioral therapy actually improve results?

In STEP 3, a 68-week randomized trial in 611 adults, all participants received intensive behavioral therapy comprising 30 counseling visits plus an initial eight-week low-calorie diet. Estimated mean body weight change was −16.0 percent with semaglutide 2.4 mg versus −5.7 percent with placebo. The placebo arm in that trial lost more than twice what the placebo arm lost in the pivotal trial with standard lifestyle intervention alone.

What happens if I stop taking semaglutide?

STEP 4 randomized 803 participants who had reached the maintenance dose to continue semaglutide or switch to placebo for 48 weeks. Mean body weight change from week 20 to week 68 was −7.9 percent with continuation versus +6.9 percent with the switch. In the STEP 1 extension, participants regained 11.6 of the 17.3 percentage points they had lost within a year of stopping, ending at a net 5.6 percent reduction.

Would a higher dose produce more weight loss?

Not reliably, and dose is not a self-directed lever. Ozempic labeling instructs prescribers to follow a stepwise escalation specifically to reduce the risk of gastrointestinal adverse reactions, with a maximum recommended dosage of 2 mg once weekly. In the trial comparing 2 mg with 1 mg, the difference between arms in body weight change at week 40 was not statistically significant. Any regimen change belongs to your prescriber.

How long do the weight trials run before reporting results?

The pivotal semaglutide weight trials ran 68 weeks, and 16 of those weeks were dose escalation before participants reached the maintenance dosage. STEP 4 added a 20-week run-in before randomization, then 48 more weeks. Any headline percentage you see is an endpoint measured after roughly a year and a quarter of continuous treatment, not a figure from the first weeks or months.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.